ANTI-c-MET DRUG CONJUGATE AND USE THEREOF Russian patent published in 2024 - IPC C07K16/28 A61K39/395 A61P35/00 A61K47/68 

FIELD: biotechnology.

SUBSTANCE: described is a group of inventions comprising a humanized antibody targeting c-Met, or an antigen-binding fragment thereof, an isolated polynucleotide encoding the antibody or an antigen-binding fragment thereof, an expression vector, a host cell for producing an antibody or an antigen-binding fragment thereof, a method for producing an antibody or an antigen-binding fragment thereof, an antibody-drug conjugate targeting c-Met, a pharmaceutical composition for treating or preventing c-Met-positive cancer, use of an antibody or an antigen-binding fragment thereof, a polynucleotide, an expression vector, an antibody-drug conjugate or a pharmaceutical composition in the manufacture of a drug for the treatment or prevention of c-Met-positive cancer, method of treating a disease, wherein the disease is c-Met-positive cancer, a kit for detecting c-Met-positive cancer, a recombinant protein targeting c-Met and the use of the antibody or antigen-binding fragment in the manufacture of a recombinant protein.

EFFECT: invention extends the range of agents targeting c-Met.

29 cl, 8 dwg, 8 tbl, 10 ex